• Innovative breast cancer screening

    2D and 3D mammography may miss cancers in dense breasts 1, 2, potentially delaying diagnosis in these women. Both dense breast tissue and cancer appear white on a mammogram, creating a dangerous camouflage effect and a dilemma for radiologists whose goal is to find breast cancer as early as possible.
  • Improve breast cancer detection

    Mammography may miss over 1/3 of cancers in dense breasts.1 The InveniaTMABUS 2.0 (Automated Breast Ultrasound System) is a comfortable, nonionizing alternative to other supplemental screening options for women with dense breast tissue. When used in addition to mammography, Invenia ABUS 2.0 can improve breast cancer detection by 37.5 percent over mammography alone.2 Learn more about Invenia ABUS 2.0 by downloading the brochure.
  • Why is Invenia ABUS 2.0 screening needed?

    Approximately 40% of women have dense breasts 4, one of the strongest common risk factors for developing breast cancer 5.  Having dense breasts increases a woman's chance of developing breast cancer by four to six times 6, and seventy-one percent of breast cancers are found in dense breasts. 7 Learn more about breast density by downloading a breast density informational sheet.
  • What are the steps in an Invenia ABUS 2.0 exam?

    The Invenia ABUS 2.0 acquisition process uses 3D ultrasound technology to comfortably and quickly image women with dense breast tissue. Each exam takes approximately 15 minutes.

    View the Invenia ABUS 2.0 acquisition process video.

evidence shows mammography ultrasounds aren't always reliable

Invenia ABUS 2.0 can improve early detection

  • Clinical evidence is growing about the effectiveness of ultrasound for finding small, node-negative, invasive cancers missed by mammography. Invenia ABUS 2.0 supplemental imaging is designed for the screening environment, specifically for dense breast imaging. Invenia ABUS 2.0 diminishes operator variability and creates 3D ultrasound volumes to enable comprehensive analysis and comparison to multimodality exams.

    Download our case studies detailing how ABUS helped uncover hidden cancers below.

Clinical impact

Discover real-world outcomes and its clinical impact -- from the effectiveness of breast screening to improved cancer detection and economic outcomes.

Economic impact


These complimentary webinars feature experienced ABUS users who discuss ABUS in clinical practice.

What are clinicians and patients saying about their experience with ABUS?

From clinicians to patients, ABUS users discuss the clinical need for supplemental screening for dense breasts and how ABUS has performed in clinical practice. Patients and clinicians alike provide their impressions of ABUS supplemental screening for dense breasts and how it has benefited them. For more information on breast care for patients, please visit knowyourrisk.gehealthcare.com
  • Technology designed for screening

    GE Healthcare is the sole provider of FDA-approved ultrasound technology for use as a supplemental screening for women with dense breast tissue. From its remarkable architecture to its advanced imaging algorithms, Invenia ABUS 2.0 is engineered for automated screening. Besides increased detection, the Invenia ABUS 2.0 is designed for reproducibility, ease of use, and both patient and operator comfort.

    cSound Imaging

    Invenia ABUS 2.0 uses the powerful cSound Imageformer, a software-based graphics processor, that provides a repeatable and operator-independent acquisition method to achieve consistent, high-quality results. cSound imaging allows significantly more data to be collected and used to create every image. Traditional hand-held ultrasound parameters such as focal zones and gain are automatically optimized. Because no image manipulation is required, high image quality is consistent from operator to operator with the touch of a button.

    Intelligent imaging algorithms

    Advanced algorithms automate the imaging process to help provide remarkable image quality and reproducibility from user to user, including: tissue equalization, nipple shadow compensation, breast border detection and chest wall detection. These are all designed to eliminate the distractions, and focus the radiologist's attention on the most important data - the anatomy.

    Comfort for operators and patients

    The gentle shape of the Reverse Curve™ transducer follows the natural contour of the breast, providing patient comfort, even compression and full contact and helps ensure comprehensive coverage. Since no two women are identical, exams can be customized with programmable scan protocols, adjustable scan depths, and compression levels. The operator can also shorten scan time once breast tissue acquisition is complete.

    Intuitive and streamlined reading

    The Invenia Viewer is designed for fast, efficient workflow for reading and reporting, allowing radiologists to quickly review, interpret and archive patient exams. Based on Windows®10 and powerful processing, the Invenia Viewer incorporates intuitive user interface icons and multiple viewing and hanging protocols, which can be customized by the user.

    Invenia Viewer also provides the coronal view, which acts as a roadmap for evaluating the entire breast. This global perspective offers better visualization of architectural distortions and multifocal disease. Reconstructed 2-mm-thick coronal slices display constant orientation and location from the nipple, making it easy to evaluate the breast from the skin line to the chest wall. Correlations with other projections and planes are easily achieved.


Mastery Program for Physicians and Technologists is led by experienced and certified peer educators to help rapidly build confidence to read Invenia ABUS 2.0 images. Technologist training occurs on-site for your convenience and offers up to 8 CME credits for participants.

For more information download the Invenia ABUS 2.0 Education Information Sheet.



1. Mandelson et al. J Natl Cancer Inst 2000; 92:1081–1087.
2. Tagliafico, Massimo Calabrese et al, Journal of Clinical Oncology 2016 34:16, 1882-1888.
3. Brem et al, Radiology, March 2015.
4. Pisano et al. NEJM 2005; 353: 1773.
5. Engmann NJ, et al, JAMA Oncol. 2017;3(9):1228-1236
6. Boyd NF et al. Mammographic Density and the Risk and Detection of Breast Cancer. NEJM 2007; 356: 227-36.
7. Arora N, King TA, Jacks LM., Ann Surg Onc, 2010; 17:S211-18.